文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-N188 在多癌种中靶向 Nectin-4 表达的转化 PET 成像

Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68Ga-N188.
PubMed 文献 · J Nucl Med · 2024-05-06

62例16种癌症患者行68Ga-N188与18F-FDG PET/CT头对头成像,36例分析SUVmax与免疫组化nectin-4表达的相关性。68Ga-N188 SUVmax与膜性nectin-4表达正相关(r=0.458;P=0.005),与胞质表达无关联。患者基于分析的检出率两者相当(95.00%[57/60] vs. 93.33%[56/60])。

要点

  • 68Ga-N188 PET的SUVmax与膜性nectin-4表达正相关(r=0.458;P=0.005)。
  • 68Ga-N188与18F-FDG的患者检出率相当(95.00%[57/60] vs. 93.33%[56/60])。
  • 胰腺癌中68Ga-N188对残留或局部复发灶检测显示潜在优势。

核心结论

  • 68Ga-N188 PET成像与膜性nectin-4表达的相关性提示其有潜力作为筛选可能从恩诺单抗维多汀(enfortumab vedotin)治疗中获益患者的有效工具。
  • PET成像结果为在多种肿瘤中探索nectin-4靶向治疗提供了证据。
  • 68Ga-N188可能改善胰腺癌的再分期,但需要在有足够把握度的前瞻性环境中进一步评估。

研究设计与样本

  • 62例16种癌症患者接受头对头68Ga-N188与18F-FDG PET/CT成像,用于初始分期或检测复发和转移。
  • 在62例患者中的36例分析了病灶SUVmax与免疫组化染色确定的nectin-4表达的相关性。

主要发现

  • 68Ga-N188的SUVmax与所测多种肿瘤类型中的膜性nectin-4表达呈正相关(r=0.458;P=0.005)。
  • SUVmax与胞质nectin-4表达之间未观察到关联。
  • 患者基于分析的68Ga-N188与18F-FDG PET/CT检出率相当(95.00%[57/60] vs. 93.33%[56/60])。
  • 在胰腺癌患者中,68Ga-N188对检测残留或局部复发肿瘤显示出潜在优势,该优势可能有助于临床决策。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 68Ga-N188可能改善胰腺癌的再分期,但需要在有足够把握度的前瞻性环境中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nectin cell adhesion molecule 4 (nectin-4) is a transmembrane protein overexpressed on a variety of cancers and plays an important role in oncogenic and metastatic processes. The nectin-4-targeted antibody-drug conjugate enfortumab vedotin has been approved for treating locally advanced or metastatic urothelial cancer, but the efficacy in other types of cancer remains to be explored. The aim of this study was to evaluate the feasibility of nectin-4-targeted PET imaging with 68Ga-N188 as a noninvasive method to quantify membranous nectin-4 expression in multiple tumor types-an approach that may provide insight for patient stratification and treatment selection. Methods: Sixty-two patients with 16 types of cancer underwent head-to-head 68Ga-N188 and 18F-FDG PET/CT imaging for initial staging or detection of recurrence and metastases. Correlation between lesion SUVmax and nectin-4 expression determined by immunohistochemistry staining was analyzed in 36 of 62 patients. Results: The SUVmax of 68Ga-N188 had a positive correlation with membranous nectin-4 expression in the various tumor types tested (r = 0.458; P = 0.005), whereas no association was observed between the SUVmax and cytoplasmic nectin-4 expression. The detection rates for patient-based analysis of 68Ga-N188 and 18F-FDG PET/CT examinations were comparable (95.00% [57/60] vs. 93.33% [56/60]). In patients with pancreatic cancer, 68Ga-N188 exhibited a potential advantage for detecting residual or locally recurrent tumors; this advantage may assist in clinical decision-making. Conclusion: The correlation between nectin-4-targeted 68Ga-N188 PET imaging and membranous nectin-4 expression indicates the potential of 68Ga-N188 as an effective tool for selecting patients who may benefit from enfortumab vedotin treatment. The PET imaging results provided evidence to explore nectin-4-targeted therapy in a variety of tumors. 68Ga-N188 may improve the restaging of pancreatic cancer but requires further evaluation in a powered, prospective setting.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Duan X, Chen X, et al. Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68Ga-N188. J Nucl Med. 2024. PMID: 38719240. doi:10.2967/jnumed.123.266830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。